# **Persistent Systems (PERSYS)**



CMP: ₹ 5,600

Target: ₹ 6,500 (16%)

Target Period: 12 months

October 24, 2024

# Strong execution!

**About the stock**: Persistent Systems (Persistent) offers cloud, data, product & design led services to BFSI, healthcare & hi-tech verticals.

- Persistent had a strong year (FY24) with revenue growth of 14.5% in dollar terms & rupee revenue growth of 17.6%
- Healthy double digit return ratio (with RoCE of 28.8%)

**Q2FY25 Performance:** Persistent reported revenues at US\$345.5 mn, up 5.3% QoQ/18.4% YoY. In CC terms, revenue was up 5.1% sequentially. In absolute terms it reported EBIT of ₹406.2 crore, up 5.8% QoQ/ 28.8% YoY while EBIT margins remained stable at 14%, flat QoQ/up 30 bps YoY. The PAT stood at ₹325 crore, up 6.1% QoQ/23.4% YoY realising into margins of 11.2%, flat QoQ/ up 30 bps YoY.

#### **Investment Rationale**

- Sustainable revenue and margin growth momentum: Persistent has maintained its target to achieve revenue of US\$2 bn by FY27 (implying a CAGR of 19%). On the margins front, the company remains confident of improving margins by 200-300 bps over 2-3 years on the back of various margin levers such as slower pace of sales and marketing investments, pricing, right shoring and higher proportion of platform-based services which have higher profitability than normal deals. We believe the company's dollar revenue will grow at CAGR of ~19% between FY24-27E, compared to CAGR of 19.8% between FY19-24. We also bake in steady margins expansion and expect EBIT margins of 14.5%/15.6%/16.6% in FY25E/26E/27E.
- Strong deal pipeline, order book and T-100 program to boost growth in H2: The TCV came at record high of US\$529 mn (up 14% QoQ/10% YoY) with new bookings contributing US\$390 mn and management expects this number to go even higher in Q3 due to higher renewals. ACV stood at \$348 mn, of which \$219 mn came from new bookings. The company expects to maintain healthy QoQ growth despite seasonality and furloughs in its BFSI and Hi-tech verticals in Q3 on the back of this strong and broad-based order book and pipeline. It also launched the T100 program (initiative focussed on scaling Top 100 accounts) which is centered on four key pillars Talent Amplification, Value Maximization, AI-driven Innovation and Ecosystem Leadership.
- Increased focus on GenAl: On the Al front, it has developed a robust strategy
  focused on two key areas: Al for technology and Al for business and plans to
  integrate Al across all verticals. It has launched platforms like SASVA and
  iAura and sees rapid adoption for its GenAl Hub across industries.

#### **Rating and Target Price**

- We expect earnings growth of ~25.8% over FY24-27E with diversified portfolio and increased traction for its GenAl platforms to be a key catalyst of its long-term growth.
- We assign BUY rating on the stock, valuing it at target price of ₹ 6,500;
   at 46x P/E on FY27E EPS.





Particulars	
Particular	Amount
Market Cap (₹ Crore)	86,222
Total Debt (₹ Crore)	171
Cash & Invests (₹ Crore)	1,296
EV (₹ Crore)	85,097
52 week H/L	5798/ 1420
Equity capital	77.0
Face value	5.0
Shareholding pattern	

	Dec-23	Mar-24	Jun-24	Sep-24
Promoter	31	31	31.0	31
FII	25	25	22.6	23
DII	26	26	28.2	27
Public	18	18	18.2	19

#### 6000 26000 5000 22000 4000 18000 14000 2000 1000 10000 Oct-24 -Oct-23 Apr-24 Oct-22 0ct-21 Persistent (LHS) Nifty (RHS)

#### Key risks

**Price Chart** 

- Continued weakness in Hi-Tech vertical:
- Better than expected revenue growth owing to T-100 program

#### **Research Analyst**

Bhupendra Tiwary, CFA bhupendra.tiwary@icicisecurities.com

CA Anjini Sharma anjini.sharma@icicisecurities.com

Deep Thosani deep.thosani@icicisecurities.com

### **Key Financial Summary**

(₹ Crore)	FY22	FY23	FY24	5 Year CAGR (FY19-24)	FY25E	FY26E	FY27E	3 Year CAGR (FY24-27E)
Net Sales	5,711	8,351	9,822	23.9%	11,859	14,167	16,873	19.8%
EBITDA	958	1,519	1,724	6.0%	2,038	2,593	3,257	23.6%
EBITDA Margins (%)	16.8	18.2	17.6		17.2	18.3	19.3	
Net Profit	690	921	1,093	47.4%	1,355	1,717	2,177	25.8%
EPS (₹)	44.8	59.8	71.0		87.9	111.5	141.3	
P/E (x)	124.9	90.7	75.5		63.7	50.2	39.6	
RoCE (%)	23.1	27.3	28.8		29.6	31.2	32.3	
RoE (%)	20.5	23.2	22.1		23.3	24.2	25.0	

### 1

## Performance highlights and Outlook

- Revenue Performance: The company reported revenues at US\$345.5 mn, up 5.3% QoQ/18.4% YoY, marking its 18th consecutive quarter of growth. In CC terms, revenue was up 5.1% sequentially while in rupee terms it stood at ₹2,897 crore, up 5.8% QoQ/20.1% YoY.
- Other Income: The company has had a onetime gain ₹80 mn on account
  of pre-closure of some lease premises in Pune and Indore, which were
  underutilized. Additionally, it invested in newer facilities in Chennai and
  Hyderabad
- Margin Performance: In absolute terms it reported EBIT of ₹406.2 crore, up 5.8% QoQ/ 28.8% YoY while EBIT margins remained stable at 14%, flat QoQ/up 30 bps YoY aided by tailwinds of 120 bps from improved utilization rates, 70 bps from reduced subcon costs, 50 bps from lower resale business, 30 bps from forex gains, 60 bps due to absence of visa cost and balance 130 bps benefit from a combination of pricing and right shoring which were mitigated by headwinds of 210 bps from wage hikes, 130 bps from absence of benefits from policy rationalisation initiatives, 60 bps incremental impact of ESOP's issuance and 60 bps from lower earnout credit. The PAT stood at ₹325 crore, up 6.1% QoQ/23.4% YoY realising into margins of 11.2%, flat QoQ/ up 30 bps YoY.
- Geography performance: Geography wise North America (81.3% of the mix) and Europe (7.9% of the mix) reported a sequential growth of 6.1% and 6.6 while India (9.2% of the mix) and ROW (1.6% of the mix) declined 1.2% and 0.9% QoQ
- Segment Performance: Segment wise Healthcare (27.8% of the mix), BFSI (31.5% of the mix) and TMT (40.7% of the mix) grew sequentially by 9.6%, 7.7% & 0.8% respectively.
  - Hi-Tech and BFSI Segment: Hi-Tech segment saw a continued muted performance for the 4th consecutive quarter. While, BFSI reported a strong sequential growth. Management stated that Hi-Tech and BFSI will see some furloughs in Q3. However, the Hi-Tech segment is expected to be bottoming out and will see a revival in the coming quarters. It further mentioned that the recent rate cuts are expected to improve the discretionary spends which will further bolster the BFSI and the Hi-Tech segments.
- Deal Wins: TCV for the quarter came at US\$529 mn, with new bookings contributing US\$390 mn (highest ever quarterly bookings). The company has also launched T100 program, an initiative focused on top 100 clients. The program is designed to drive better customer value and deepen relationships. The management indicated that increased new deal wins have been driven by platform led engagements. Further it mentioned that many deal wins involve setting up large teams, new outsourced work and transitioning works from incumbents.
- Al/GenAl: On the Al front, the company has developed a robust strategy focused on two key areas: Al for technology and Al for business and plans to integrate Al across all verticals.
  - Al for technology: The company has launched SASVA 2.0 Aldriven platform designed to enhance software engineering services across the product development lifecycle.
  - Al for business: The company is seeing rapid adoption of the GenAl Hub and its iAURA platform. It has expanded its GenAl Hub library of pre-built Al models and use cases by over 50% since Q1FY25. The company's iAura platform is a suite of data tools for Al and machine learning implementations. Persistent has also partnered with key ecosystem players such as Google Cloud to create generative Al offerings. Further, the management didn't disclose the



revenue generated from the AI business, but stated that they're trying to infuse AI into everything they do.

- **Update on acquisitions:** Following to their Q1 announcement, the company **has fully integrated its Starfish acquisition**. They're enhancing their contact centre portfolio with AI-enabled administration and workflow assistance, and expect some early deal wins from this portfolio to reported from the end of the next quarter.
- Revenue and Margin Guidance/Aspiration: The management stated that it expects the margins to expand by 200-300 bps over the span of next 2-3 years on the back of its cost optimization program and operational efficiencies such as right shoring, slower pace of sales and marketing investments and pricing. It further maintained its aspirations to achieve the US\$ 2 bn revenue mark, implying a CAGR of 19% over FY24-27.
- Attrition & Employee addition: The total employees for the quarter stood at 23,337, after a net reduction of 282 employees, given the company's focus on improving its utilisation. Its attrition for the quarter remained was up 10 bps QoQ at 12%.

	Q2FY25	Q2FY24	YoY (%)	Q1FY25	QoQ (%)	Comments
Revenue (USD mn)	345.5	291.7	18.4	328.2		Revenue grew by 5.1% QoQ in CC terms
Revenue	2,897.2	2,411.7	20.1	2,737.2	5.8	
Employee expenses	1,929.4	1,612.7	19.6	1,832.9	5.3	
Gross Margin	967.8	799.0	21.1	904.3	7.0	
Gross margin (%)	33.4	33.1	28 bps	33.0	37 bps	
Other expenses	487.0	393.8	23.7	449.1	8.4	
EBITDA	480.7	405.2	18.6	455.2	5.6	
EBITDA Margin (%)	16.6	16.8	-21 bps	16.6	-4 bps	
Depreciation & amortisation	74.5	74.4	0.1	71.2	4.6	
EBIT	406.2	330.8	22.8	384.0	5.8	
EBIT Margin (%)	14.0	13.7	31 bps	14.0	-1 bps	EBIT margins remained stable at 14%, flat QoQ/up 30 bps YoY aided by tailwinds of 120 bps from improved utilization rates, 70 bps from reduced subcon costs, 50 bps from lower resale business, 30 bps from forex gains, 60 bps due to absence of visa cost & balance 130 bps benefit from a combination of pricing & right shoring which were mitigated by headwinds of 210 bps from wage hikes, 130 bps from absence of benefits from policy rationalisation initiatives, 60 bps incremental impact of ESOP's issuance and 60 bps from lower earnout credit.
Other income	28.3	25.0	13.2	16.5	71.2	
PBT	434.5	355.8	22.1	400.5	8.5	
Tax paid	109.5	92.5	18.4	94.1	16.3	
PAT	325.0	263.3	23.4	306.4	6.1	

Source: Company, ICICI Direct Research

FY25E

1,799

320

(61)

FY26E

2,290

383

43

₹ crore

FY27E

2,902

456

51

# **Financial Summary**

Tubibit 2. Drofit and loss st	~+~~~~~			₹ erere	Exhibit 2. Cook flow statemen	- m+
Exhibit 2: Profit and loss sto (Year-end March)	FY24	FY25E	FY26E	₹ crore FY27E	Exhibit 3: Cash flow statemed (Year-end March)	ent F
Total Revenues	9,822	11,859	14,167	16,873	PBT	1.4
Growth (%)	17.6	20.7	19.5	19.1	Depreciation & Amortization	
Employee & Subcon costs	6,523	7,839	9,279	10,968	WC changes	(2
Total Operating Expenditure	8,097	9,821	11,574	13,617	Other non cash adju.	
EBITDA	1,724	2,038	2,593	3,257	CF from operations	1,2
Growth (%)	13.5	18.2	27.2	25.6	Capital expenditure	(4
Depreciation & Amortization	309	320	383	456	$\Delta$ in investments	
Other Income	81	82	80	101	Other investing cash flow	
Interest	-	-	-	-	CF from investing Activities	(4
PBT before Excp Items	1,496	1,799	2,290	2,902	Issue of equity	
Growth (%)	17.8	20.3	27.3	26.7	$\Delta$ in debt funds	(2
Tax	354	445	572	726	Dividends paid	(4
PAT before Excp Items	1,142	1,355	1,717	2,177	Other financing cash flow	(
Exceptional items	49	-	-	-	CF from Financial Activities	(5
PAT before MI	1,093	1,355	1,717	2,177	$\Delta$ in cash and cash bank bala	
Minority Int & Pft. frm asso	-	-	-	-	Effect of exchange rate chang	
PAT	1,093	1,355	1,717	2,177	Opening cash	(
Growth (%)	18.7	23.9	26.8	26.7	Cash c/f to balance sheet	1,0
Diluted EPS	71	88	111	141	Source: Company, ICICI Direct Research	
EPS (Growth %)	18.7	23.8	26.8	26.7		

Other non cash adju.	11	(82)	(80)	(101)
CF from operations	1,221	1,532	2,063	2,582
Capital expenditure	(486)	(949)	(1,133)	(1,350)
$\Delta$ in investments	(43)	-	-	-
Other investing cash flow	60	82	80	101
<b>CF from investing Activities</b>	(469)	(867)	(1,053)	(1,249)
Issue of equity	161	-	-	-
$\Delta$ in debt funds	(223)	-	-	-
Dividends paid	(408)	(486)	(448)	(568)
Other financing cash flow	(123)	(30)	(30)	(30)
CF from Financial Activities	(594)	(516)	(478)	(598)
$\Delta$ in cash and cash bank bala	158	149	532	735
Effect of exchange rate chang	-	-	-	-
Opening cash	903	1,023	1,172	1,703

1,023

1,172

1,703

2,438

FY24

1,448

309

(205)

Source: Company, ICICI Direct Research

(Year-end March) Liabilities	FY24	D/2FF		
l ighilities		FY25E	FY26E	FY27E
Liubiliuco				
Equity	77	77	77	77
Reserves & Surplus	4,881	5,749	7,018	8,627
Networth	4,958	5,826	7,095	8,704
Minority Interest	-	-	-	-
Long term Liabilties & provisi-	232	243	256	271
Source of funds	5,189	6,069	7,351	8,975
Assets				
Net fixed assets	706	1,057	1,470	1,955
Net intangible assets	457	765	1,134	1,572
Goodwill	1,091	1,091	1,091	1,091
Other non current assets	442	442	442	442
Investments	554	554	554	554
Debtors	1,676	1,787	2,135	2,543
Current Investments	273	273	273	273
Cash & Cash equivalents	1,023	1,172	1,703	2,438
Other current assets	1,152	1,152	1,152	1,152
Trade payables	814	709	847	1,009
Current liabilities	1,370	1,514	1,754	2,035
Application of funds	5,189	6,069	7,351	8,975

Exhibit 5: Key ratios				
(Year-end March)	FY24	FY25E	FY26E	FY27E
Per share data (₹)				
Diluted EPS	71.0	87.9	111.5	141.3
Cash Per Share	66.4	76.1	110.6	158.3
BV	322.0	378.2	460.6	565.0
DPS	26.0	26.3	24.3	30.7
Operating Ratios (%)				
EBITDA Margin	17.6	17.2	18.3	19.3
PBT Margin	15.2	15.2	16.2	17.2
PAT Margin	11.1	11.4	12.1	12.9
Turnover Ratios				
Debtor days	62	55	55	55
Creditor days	30	22	22	22
Return Ratios (%)				
RoE	22.1	23.3	24.2	25.0
RoCE	28.8	29.6	31.2	32.3
RoIC	36.3	37.1	41.1	44.7
Valuation Ratios (x)				
P/E	75.5	63.7	50.2	39.6
EV / EBITDA	49.4	41.7	32.6	25.7
Market Cap / Sales	8.8	7.3	6.1	5.1
Solvency Ratios				
Current Ratio	1.3	1.3	1.3	1.2
Quick Ratio	1.3	1.3	1.3	1.2

Source: Company, ICICI Direct Research



#### **RATING RATIONALE**

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head - Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, Third Floor, Brillanto House, Road No 13, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com

#### ANALYST CERTIFICATION

I/We, Bhupendra Tiwary, CFA, MBA (Finance), Anjini Sharma, CA, Deep Thosani, MBA (Finance), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are

# Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.